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p16INK4Aa b s t r a c t
Background and Purpose: Squamous cell carcinomas of the anal canal are associated with infection with
Human Papilloma Viruses (HPVs). Chemo-radiotherapy (CRT) gives 70% 3-year relapse-free survival.
Improved predictive markers and therapeutic options are required.
Methods: Tumours from 153 patients treated with radical chemo-radiotherapy (50.4 Gy in 28# with con-
current Mitomycin and 5-Fluorouracil between 2004 and 2009) were retrieved and immunohistochem-
istry performed for p16INK4A, p53 and EGFR and correlated with outcome. Primary and relapsed samples
were analysed for mutations in KRAS.
Results: 137/153 (89.5%) stained moderately or strongly for p16INK4A. p16INK4A correlated strongly with
outcome. 37/137 patients demonstrating moderate/strong p16INK4A expression relapsed (27.0%), as
opposed to 10/16 (62.5%) with absent/weak staining (log rank test p < 0.001). p16 and p53 expression
were inversely correlated. p16INK4A negative tumours were more frequent in men. p16INK4A negative
patients had signiﬁcantly worse overall survival (p < 0.001). No mutations in KRAS were identiﬁed in pri-
mary tumours or relapses following treatment.
Conclusions: p16INK4A is strongly associated with relapse in SCC of the anus and identiﬁes patients with
very poor rates of relapse-free and overall survival. Primary and recurrent anal cancer expresses wild type
KRAS, unaffected by treatment, supporting trials targeting EGFR in poor risk/recurrent anal cancer.
 2013 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy
and Oncology 109 (2013) 146 151–
Open access under CC BY-NC-ND license.Squamous cell carcinomas of the anal canal remain relatively
rare (less than 1000 cases per annum in the UK) though are
increasing in incidence within the developed world [1] for reasons
unknown. The standard of care in the UK for all but the earliest
tumours is radical chemo-radiotherapy (CRT – 50.4 Gy in 28 frac-
tions plus concurrent 5-Fluorouracil and Mitomycin [2]). Prelimin-
ary results of the United Kingdom National Anal Cancer Trial (ACT
II) show excellent complete response rates (95%) and 3-year recur-
rence free survival rates of 75% in T1/T2 tumours, and 68% for more
advanced T3/T4 tumours [3]. However acute toxicities (skin, gas-
trointestinal and haematological) are frequent and many patients
require signiﬁcant support or even admission during treatment.
Equally patients may experience long-term changes in bowel andsexual function. For those patients who relapse following CRT,
approximately 40% may be salvaged by abdomino-perineal resec-
tion [4] but locally advanced or metastatic disease is incurable
with only limited responses to palliative chemotherapy. Overall,
some patients cannot tolerate this combination of treatment and
others will not be cured by it, hence new therapeutic approaches
and predictive factors are required.
The majority of anal cancers are believed to be caused by infec-
tion with high risk subtypes of Human Papilloma Virus (HR HPV) in
common with squamous cell carcinomas of the cervix, vulva and
penis [5]. In addition it has recently been appreciated that a signif-
icant proportion of head and neck cancers (oropharynx in particu-
lar) are similarly linked to HR HPV infection and indeed this is
behind the marked rise in oropharyngeal cancers within the UK
and across the developed world [6–8].
Radical chemo-radiotherapy is central to treatment paradigms
across these cancer types. p16INK4A (p16) also known as Cyclin-
dependent kinase inhibitor 2A (CDKN2A) is a cell cycle regulatory
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CDK6 interacting with Cyclin D. p16 expression is normally
repressed by the pRB-E2F complex, but this suppression is inhib-
ited by the HPV viral protein E7 resulting in increased expression
of p16. Immunohistochemistry for p16 is hence a surrogate for
the presence of genomic HR HPV in cervix and head and neck
squamous cell carcinomas (HNSCC) [9] and is predictive of signiﬁ-
cantly improved response to treatment (with chemo-radiotherapy)
and overall survival. Published data on a series of 47 patients sug-
gest p16 immunohistochemistry relates to HPV involvement in
anal cancer and might be a prognostic factor [10]. In that series,
39 patients (83%) stained positive for p16 with 35 (75%) showing
evidence of HPV by PCR. There was a signiﬁcant difference in dis-
ease free survival (p16+ve DFS 63.1% vs. p16ve 15.6%,
p < 0.001). In a previous study involving small numbers of patients
(13) there appeared to be improved survival based on another sur-
rogate for HPV positivity, MCM7 [11].
Cellular transformation by HPV is effected through the produc-
tion of the viral proteins E6 and E7 that down regulate p53/pRB
function respectively [12]. This may be distinct from alternative
mechanisms that lead to HPV negative tumours at the same ana-
tomical sites. Indeed miRNA gene expression data suggests HPV
positive HNSCC has more in common with cervical cancer than
HPV negative HNSCC [13]. With respect to anal cancer gene expres-
sion proﬁles show two distinct groups of tumours – one associated
with HPV/p16 and the other not [11].
Another difference seen between HPV associated tumours and
their non-HPV counterparts is in the frequency of mutations in
p53, reportedly mutually exclusive with HPV infection in HNSCC
[14]. Wild type p53 is rapidly degraded under normal conditions
within the cell whereas mutated p53 undergoes conformational
changes that result in accumulation and increased immunohisto-
logical staining [15]. Previous data suggests that immunohisto-
chemistry for p53 may predict outcome to chemo-radiotherapy
in anal cancer [16–18] though this effect is not a consistent ﬁnding
(for a systematic review see [19]).
Theremay be direct therapeutic implications of themultiple bio-
logical differences between HPV positive and negative cancers at
these sites, with the former retaining intact apoptotic mechanisms
and lattermore likely to over express EGFR [20]. In the case of penile
cancer it appears that functional EGFR signalling is more important
in HPV negative cancers [21]. In HNSCC there is a survival beneﬁt for
the addition of Cetuximab (the monoclonal antibody against EGFR)
to chemotherapy in the palliative setting [22]. In colorectal cancer
where Cetuximab is also widely used it is appreciated that tumours
with activating mutations in KRAS (a frequent early step in a
common molecular pathway to colorectal carcinogenesis) are
unsurprisingly insensitive to upstream inhibition of EGFR and
KRAS mutation status has entered routine clinical use as a predic-
tive biomarker of efﬁcacy of Cetuximab in this disease type.
We therefore hypothesise that p16 positive anal cancers may
demonstrate improved response rates to concurrent chemo-radio-
therapy whilst conversely EGFR expression may be more frequent
in p16 negative tumours and associated with a worse prognosis,
justifying a trial combining EGFR targeting agents with radiother-
apy in these patients. In addition we have investigated KRAS muta-
tion status in a cohort of patients that relapse to further support
trials targeting EGFR.Methods
Ethics
This work was granted ethical approval by the relevant ethics
committees (11/LO/1032) and prospective consent was obtained
for KRAS testing (09/H1101/54).Clinical data retrieval
Clinical details were retrieved for patients treated with radical
chemo-radiotherapy for non-metastatic squamous cell carcinomas
of the anus and anal canal between 2004 and 2009 inclusive at the
Sussex Cancer Centre, Brighton and the Kent Oncology Centre,
Maidstone, UK. Patient demographics, HIV status, tumour stage,
radiotherapy and chemotherapy details, treatment response, sub-
sequent relapse and last follow up date were obtained from patient
case notes.Pathology review and immunohistochemical staining
Formalin ﬁxed parafﬁn embedded samples were obtained
under anonymous study numbers and haematoxylin and eosin
slides reviewed to conﬁrm the presence of invasive tumour in
the relevant blocks. Slides were then cut and stained for p16, p53
and EGFR using the automated Dako Autostainer Link 48 system
and PT links. Sections were ﬁrst deparafﬁnised and antigen
retrieved. Slides were preheated to 65 C and placed in buffer for
5 min. Staining for p16 was carried out using mouse antihuman
monoclonal p16 antibody within the p16 CINtec Histology V.Kit
(mtm laboratories AG, Heidelberg, Germany) with cervical cancer
specimens as a positive control. EGFR and p53 primary antibodies
were obtained from Dako (Denmark): EGFR was used at 1:150 dilu-
tion and p53 at 1:30 dilution. All reagents were used at optimal
dilution as speciﬁed by the manufacturer.Scoring
Slides stained for p16, p53 and EGFR were scored independently
by two consultant histopathologists (KA and AW). Where scores
differed, slides were reviewed by both pathologists and a consen-
sus score agreed. Slides were scored 0–3 (absent, weak, moderate
and strong) for p16, p53 and EGFR and tumours subsequently
grouped as positive (2/3) or negative (0/1) for subsequent analysis.
p16 was considered absent if <5% cells stained positive. p53 stain-
ing was considered high if >5% cells scored 3.KRAS mutation testing
Samples from relapsed patients (primary and corresponding
relapse) were analysed for mutations in KRAS by a commercial lab-
oratory (Lab 21, Cambridge, UK).Statistics
Fishers exact test (2 tailed) was used to assess the association
between immunohistochemical scores and subsequent relapse
(www.graphpad.org). Pearsons correlation, Kaplan–Meier survival
curves, log rank test for survival and multivariate (Cox-regression)
analysis were performed using SPSS to investigate correlation
between clinical-pathological features and relapse-free survival.
Results
Patient demographics and treatment details (Table 1)
153 patients had been treated with radical chemo-radiotherapy
(50.4 Gy in 28 fractions with concurrent Mitomycin and 5-Fluoro-
uracil, 2004–2009) and had archived pathological material avail-
able for review. The median age of the cohort of 153 patients at
presentation was 65.5 years (range 34.2–92.7 years). 93 (60.8%)
patients were female, 60 (39.2%) male. Complete stage information
(TNM) at presentation was documented for 123 patients. Median
stage at presentation was T3N0 (Modal stage T2N0). 53/123 cases
were node positive by imaging +/ cytological conﬁrmation. HIV
Table 1
Patient characteristics and demographics.
Total N = 153
Age Median 65.5 years
Range 34.2–92.7 years
Sex Male 60 (39%)
Female 93 (71%)
Stage I T1N0 9 (6%)
II T2/3 N0 51 (33%)
IIIA T1–3N1/T4N0 26 (17%)
IIIB T4N1/Tany N2–3 38 (25%)
Unrecorded/incomplete 29 (19%)
HIV+ve Positive 9 (6%)
Negative 70 (46%)
Not performed/unrecorded 74 (48%)
148 p16 in chemoradiotherapy for anal cancerstatus was documented for 79 patients in whom the HIV+ rate was
9/79 (11.4%); 1 HIV positive patient was female, the other 8 male.Patient outcomes by clinical features (Table 2)
At a median follow up of 27.9 months, 47/153 (30.7%) patients
have relapsed. The mean time to relapse was 13.9 months (range
3–50.4 months).
Male patients had an increased risk of relapse of borderline sta-
tistical signiﬁcance. 24/60 (40.0%) male patients relapsed as
opposed to 23/93 (24.7%) females (log rank test p = 0.045). There
was no difference in the age of patients who experienced relapse
compared with those that remained disease free. The mean age
of patients that relapsed was 62.7 years (range 41.6–88.6), non-
relapsing cases had a mean age of 63.6 years (range 34.2–92.7).
In terms of stage at presentation, relapse-free survival fell from
72.7% for T1 to 57% for T4 tumours though this did not reach sta-
tistical signiﬁcance (log rank test p = 0.145). Similarly there was a
trend to increased rates of relapse with nodal burden at presenta-
tion that did not reach statistical signiﬁcance.Table 2
Clinical-pathological features and relapse rate (univariate analysis) in 153 anal cancer pat
Factor Relapse (rate) No relapse (rat
Sex (n = 153)
Male 24 (0.40) 36 (0.60)
Female 23 (0.25) 70 (0.75)
T stage (n = 133)
Tx 3 (0.30) 7 (0.70)
T1 3 (0.27) 8 (0.72)
T2 14 (0.30) 32 (0.70)
T3 13 (0.325) 27 (0.68)
T4 11 (0.42) 15 (0.58)
N stage (n = 132)
N0 23 (0.29) 56 (0.71)
N1 14 (0.63) 8 (0.37)
N2 17 (0.63) 10 (0.37)
N3 2 (0.50) 2 (0.50)
N any 33 (0.62) 20 (0.38)
p16 (n = 153)
p16 positive 37 (0.27) 100 (0.73)
p16 negative 10 (0.63) 6 (0.37)
p53 (n = 147)
p53 high (3) 13 (0.46) 15 (0.54)
p53 low (0,1,2) 34 (0.29) 85 (0.71)
EGFR (n = 148)
EGFR positive 30 (0.33) 60 (0.66)
EGFR negative 16 (0.28) 42 (0.72)There was no difference in rates of relapse in HIV positive
patients although numbers were small. 4/9 (44.4%) patients with
HIV experienced relapse as opposed to 23/70 (32.9%) HIV negative
patients (Fishers exact test p = 0.23).Outcome by immunohistochemistry for p16, EGFR and p53 (Table 2)
Samples from 153 patients were assessable with immunohisto-
chemistry for p16. 137 (89.5%) stained moderately or strongly for
p16. 147 cases were analysed for p53 staining with 28 (19%) show-
ing strong positivity (score 3). Finally 148 samples were assessable
for EGFR; 90 (61%) stained positively for EGFR in >5% cells (Fig. 1).
p16 negative cases were marginally more advanced at presenta-
tion (median stage T3N1 as opposed to T3N0 in p16 positive cases).
T3/4 tumours were more frequent in p16 negative cases (8/12 as
opposed to 57/110); 6/12 p16 negative cases were node positive
as opposed to 44/110 p16 positive tumours. There was no differ-
ence between the median age of the p16+ve (63.0 years, range
34.2–92.7) and p16ve patients (65.7 years, range 45.8–86.3, t-test
p = 0.32). Of the 9 HIV patients presenting with anal carcinoma, 8
were p16+ and 1 patient p16.
Male patients were more likely to be p16 negative; 12/60 (20%)
men having p16ve tumours as opposed to 4/93 women (4.3%
(Fishers exact test p = 0.0027)).
In univariate analysis, p16 expression correlated strongly with
outcome (relapse-free survival) in these 153 patients (Table 2 –
relapse rate 27% in moderate/strong p16 vs. 62.5% in p16 absent/
weak, Fishers exact test p = 0.0076). Kaplan–Meier curves for
relapse-free survival are shown in Fig. 2a (log rank test
p < 0.001). There was a weaker but signiﬁcant association between
strong staining for p53 and increased risk of relapse (relapse rate
13/28 = 46% in samples scoring 3 for p53 as opposed to 34/
119 = 28% in samples scoring 0, 1, or 2 for p53). This was of border-
line statistical signiﬁcance (Fishers exact test p = 0.0759, log rank
test p = 0.02) and Kaplan–Meier survival curves are shown in
Fig. 2b. There was a signiﬁcant negative correlation between p16
and p53 (R2 = 0.325, p < 0.01).ients treated with radical chemo-radiotherapy.
e) Total (rate) Log rank test (univariate)
60 (0.39) p = 0.045
93 (0.71)









53 (0.40) p = 0.119
137 (0.90) p 6 0.001
16 (0.10)
28 (0.19) p = 0.02
119 (0.81)
90 (0.61) p = 0.49
58 (0.39)
Fig. 1. Representative immunohistochemistry for anal squamous cell carcinomas (SCCs). (a–c) Haematoxylin and eosin stained sections from three anal SCCs. (d)
Corresponding adjacent section showing p16INK4A positive invasive tumour cells. (e) SCC inﬁltrating the underlying stroma exhibiting diffuse strong nuclear positivity for p53.
(f) Diffuse predominantly membranous positivity for EGFR. The overlying normal squamous epithelium shows the normal expression of EGFR in squamous epithelium with
loss of EGFR with maturation of the epithelium.
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T- and N-stage as co-variants, only p16 expression retained its
prognostic value, with a hazard ratio of 4.501 (95% CI 1.982–
10.223). Speciﬁcally, p53 expression did not have prognostic utility
in the p16 positive cases and did not separate the p16 positive
cases into groups with differing relapse rates (Fishers exact test
p = 0.4133).
There was no association between EGFR immunoreactivity and
outcome, whether samples were grouped as positive or negative or
analysed by individual immunohistochemical score (0–3). There
was no evidence of correlation between EGFR staining and scores
for either p16 or p53.Cancer speciﬁc survival and clinico-pathological features
Of 47 patients who experienced relapse, 20 (43%) proceeded to
salvage surgery (APR). Of these patients, 13 (65%) subsequently
died, all of progressive anal cancer. In univariate analysis investi-
gating p16, p53, sex, T and N stage, only p16 was associated with
a difference in cancer speciﬁc survival (Fig. 2c). Amongst p16 posi-
tive cases median survival was 65.2 months (95% CI 46.0–84.4) as
opposed to 22.3 months (95% 9.1–35.6) in p16 negative cases (log
rank test p 6 0.001).KRAS mutation status (Table 3)
Results were obtained for 36 samples from 23 patients. Relapses
were recorded as follows: local (10), nodal (7), liver (4), lung (2),
intraperitoneal (2). Of these 23 patients, 13 had samples available
and tested from both primary and relapsed tumours (Table 3). 9
had samples solely from the primary tumour and 3 had samples
tested from the site of relapse only. All primary and relapsed
tumours were wild type for KRAS. No activating mutations were
found.
Discussion
This study is the largest yet reported to investigate the prognos-
tic effect of immunohistochemistry for p16 in patients treated with
radical chemo-radiotherapy for invasive squamous cell carcinomas
of the anus. The cohort of 153 patients was treated with radical
chemo-radiotherapy as per the current UK standard of care follow-
ing the ACT2 trial [3]. Relapse rates overall were similar in this
cohort to those reported in ACT2, although higher rates of relapsewere seen in the T1/2N0 patients suggesting a degree of under
staging. This may reﬂect the fact that many were staged with CT
alone (in addition stage was unrecorded in 19% cases).
That the majority of cases stained positive for p16, a cell cycle
regulator that may also be a surrogate for HPV involvement, is in
keeping with previous epidemiological studies that suggest 80–
90% anal cancers are associated with oncogenic subtypes of HPV.
However there is little data regarding which HPV subtypes are pre-
valent within invasive anal cancers in the UK population. Evidence
of HPV involvement in HNSCC is increasing over time [5,22] and
comparative data for anal cancer are vital in terms of understand-
ing the biology of p16 expression but also the question of expand-
ing HPV vaccination to the male population.
The strong prognostic effect of p16 on outcomes with p16 neg-
ative cases having a markedly poorer outcome (37% relapse-free
survival as opposed to 73% in p16 positive cases) is in line with
other squamous cell cancers with an HPV association (cervix,
vulva, penile, oropharyngeal [23]). The data presented here are
consistent with previous ﬁndings with respect to p16 [10] and
MDM7 [11] (another surrogate for HPV) in anal cancer treated with
CRT. Reasons for the sensitivity of HPV cancers to chemo-radio-
therapy are likely to include a lower rate of activating mutations
[24] and wild type p53 [14] and reﬂect biological differences
between HPV and non-HPV pathways to transformation. This is
supported in part by the suggestion of an inverse relationship
between p53 and p16 in this cohort. Recent work in penile cancers
demonstrates activation of HER2/PI3 Kinase signalling is more fre-
quent in HPV negative cases [21].
In oropharyngeal cancer it is clear that a history of cigarette
smoking further modulates the prognostic effect of HPV associa-
tion producing three distinct groups of patients i.e. HPV+/non-
smokers with good risk disease, HPV+/smokers with intermediate
risk disease and HPV tumours with poor risk disease. Smoking
history is lacking from this cohort of anal cancers but should be
investigated in future studies to seek evidence of a parallel effect
on outcomes.
Unlike recent analysis of the chemo-radiotherapy treated
patients within the ﬁrst UK Anal Cancer trial [25] the prognostic
effect of male sex and nodal status was of borderline statistical sig-
niﬁcance in this cohort. The higher rates of p16 negative cancers
amongst men is interesting however given that male sex has pre-
viously been identiﬁed as a poor prognostic factor.
There is evidence for targeting EGFR signalling in squamous cell
carcinomas at other anatomical sites; the monoclonal antibody
Fig. 2. Kaplan–Meier relapse-free survival curves for 153 patients stratiﬁed by (a) immunohistochemistry for p16INK4A (log rank test p < 0.001) and (b) p53 (log rank test
p = 0.02) and (c) cancer speciﬁc survival for 153 cases stratiﬁed by immunohistochemistry for p16INK4A (log rank test p 6 0.001).
150 p16 in chemoradiotherapy for anal cancerCetuximab improves outcomes in HNSCC both in combination with
radical radiotherapy [26] and with chemotherapy in relapsed cases
[22]. The absence of any activating mutations in KRAS either in pri-
mary or relapsed cases in this cohort of anal cancer patients con-
trasts with colorectal cancer where mutations in KRAS are an
early step malignant transformation. This result is consistent with
previous studies [27–30] where cumulatively only 2/152 anal
cancers harboured KRAS mutations. EGFR targeting drugs could
be used in anal cancer either to intensify radical therapy (in com-
bination with chemo-radiotherapy) in poor risk cases, or in combi-
nation with chemotherapy in the palliative situation. Salvage
surgery was only possible in 43% relapses with relatively poor
subsequent outcomes, although published series report 5-year sur-
vivals of only 50–65% in such cases [32,33] highlighting the needfor improvement in the initial treatment of poor risk cases. Inten-
siﬁcation of radical local treatment must proceed with caution
however. A French trial testing the addition of Cetuximab to
chemo-radiotherapy (with concurrent cisplatin and 5-Flurouracil)
was stopped after 16 patients due to high rates of toxicity despite
decreased chemotherapy doses and mandatory Intensity Modu-
lated Radiotherapy [31]. Beyond a prognostic effect in HPV cancers,
a predictive role for p16 for any speciﬁc therapy has not yet been
elucidated though it is possible that for the reasons discussed
p16 negative cases might be more sensitive to EGFR targeting
agents [34,35].
Immunohistochemistry for p16 identiﬁes a group of patients
with such poor risk disease that the current standard of care is
insufﬁcient and if validated as an independent risk factor for
Table 3
KRAS status by demographics.
Primary tumour Treatment Relapsed tumour
1 KRAS wt Radical CRT Node – KRAS wt
2 KRAS wt Radical CRT Persistent disease – KRAS wt
3 KRAS wt Radical CRT Lung and Liver N/A
4 KRAS wt Radical CRT Liver – N/A
5 KRAS wt Radical CRT Pelvic nodes – N/A
6 KRAS wt Radical CRT Anal recurrence – KRAS wt
7 KRAS wt Radical CRT Persistent disease – KRAS wt
8 KRAS wt Radical CRT Persistent disease – KRAS wt
9 KRAS wt Radical CRT Pelvic nodes – N/A
10 KRAS wt Radical CRT Local recurrence – KRAS wt
11 N/A Radical CRT Persistent disease – KRAS wt
12 KRAS wt Radical CRT Local recurrence – KRAS wt
13 KRAS wt Radical CRT Local recurrence – KRAS wt
14 N/A Radical CRT Pelvic recurrence – KRAS wt
15 KRAS wt Radical CRT Local recurrence – KRAS wt
16 KRAS wt Radical CRT Local recurrence – KRAS wt
17 KRAS wt Radical CRT Visceral –KRAS wt
18 KRAS wt Radical CRT Liver – N/A
19 KRAS wt Radical CRT Lung – N/A
20 KRAS wt Radical CRT Inguinal node – N/A
21 KRAS wt Radical CRT Node – KRAS wt
22 KRAS wt Radical CRT Node – KRAS wt
23 N/A Surgery Node – KRAS wt
D.C Gilbert et al. / Radiotherapy and Oncology 109 (2013) 146–151 151relapse in a randomised data set such as ACT2 has the potential to
form a subgroup of patients at presentation in which to investigate
new therapeutic approaches. Equally however, only 22% relapses
overall occur in the p16 negative cases – approaches that improve
outcomes need to be assessed in the wider population. There is fur-
ther scope for additional biomarkers of relapse within the p16
positive cohort of patients to identify patients who are well served
by current treatment protocols and those in whom novel
approaches are required.Funding
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